DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mavik (Trandolapril) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

The safety experience in U.S. placebo-controlled trials included 1069 hypertensive patients, of whom 832 received MAVIK. Nearly 200 hypertensive patients received MAVIK for over one year in open-label trials. In controlled trials, withdrawals for adverse events were 2.1% on placebo and 1.4% on MAVIK. Adverse events considered at least possibly related to treatment occurring in 1% of MAVIK-treated patients and more common on MAVIK than placebo, pooled for all doses, are shown below, together with the frequency of discontinuation of treatment because of these events.

ADVERSE EVENTS IN PLACEBO-CONTROLLED HYPERTENSION TRIALS
  Occurring at 1% or greater  
  MAVIK
(N=832)
% Incidence
(% Discontinuance)
PLACEBO
(N=237)
% Incidence
(% Discontinuance)
Cough 1.9 (0.1) 0.4 (0.4)
Dizziness 1.3 (0.2) 0.4 (0.4)
Diarrhea 1.0 (0.0) 0.4 (0.0)

Headache and fatigue were all seen in more than 1% of MAVIK-treated patients but were more frequently seen on placebo. Adverse events were not usually persistent or difficult to manage.

Left Ventricular Dysfunction Post Myocardial Infarction

Adverse reactions related to MAVIK occurring at a rate greater than that observed in placebo-treated patients with left ventricular dysfunction, are shown below. The incidences represent the experiences from the TRACE study. The follow-up time was between 24 and 50 months for this study.

Percentage of Patients with Adverse Events Greater Than Placebo
Placebo-Controlled (TRACE)
Mortality Study
Adverse Event Trandolapril
N=876
Placebo
N=873
Cough 35 22
Dizziness 23 17
Hypotension 11 6.8
Elevated serum uric acid 15 13
Elevated BUN 9.0 7.6
PICA or CABG 7.3 6.1
Dyspepsia 6.4 6.0
Syncope 5.9 3.3
Hyperkalemia 5.3 2.8
Bradycardia 4.7 4.4
Hypocalcemia 4.7 3.9
Myalgia 4.7 3.1
Elevated creatinine 4.7 2.4
Gastritis 4.2 3.6
Cardiogenic shock 3.8 < 2
Intermittent claudication 3.8 < 2
Stroke 3.3 3.2
Asthenia 3.3 2.6

Clinical adverse experiences possibly or probably related or of uncertain relationship to therapy occurring in 0.3% to 1.0% (except as noted) of the patients treated with MAVIK (with or without concomitant calcium ion antagonist or diuretic) in controlled or uncontrolled trials (N=1134) and less frequent, clinically significant events seen in clinical trials or post-marketing experience include (listed by body system):

General Body Function

Chest pain.

Cardiovascular

AV first degree block, bradycardia, edema, flushing, and palpitations.

Central Nervous System

Drowsiness, insomnia, paresthesia, vertigo.

Dermatologic

Pruritus, rash, pemphigus.

Eye, Ear, Nose, Throat

Epistaxis, throat inflammation, upper respiratory tract infection.

Emotional, Mental, Sexual States

Anxiety, impotence, decreased libido.

Gastrointestinal

Abdominal distention, abdominal pain/cramps, constipation, dyspepsia, diarrhea, vomiting, nausea.

Hemopoietic

Decreased leukocytes, decreased neutrophils.

Metabolism and Endocrine

Increased liver enzymes including SGPT (ALT).

Musculoskeletal System

Extremity pain, muscle cramps, gout.

Pulmonary

Dyspnea.

Postmarketing

The following adverse reactions were identified during post approval use of MAVIK. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

General Body Function

Malaise, fever.

Cardiovascular

Myocardial infarction, myocardial ischemia, angina pectoris, cardiac failure, ventricular tachycardia, tachycardia, transient ischemic attack, arrhythmia.

Central Nervous System

Cerebral hemorrhage.

Dermatologic

Alopecia, sweating, Stevens-Johnson syndrome and toxic epidermal necrolysis.

Emotional, Mental, Sexual States

Hallucination, depression.

Gastrointestinal

Dry mouth, pancreatitis, jaundice and hepatitis.

Hemopoietic

Agranulocytosis, pancytopenia.

Metabolism and Endocrine

Increased SGOT (AST).

Pulmonary

Bronchitis.

Renal and Urinary

Renal failure.

Clinical Laboratory Test Findings

Hematology

Thrombocytopenia.

Serum Electrolytes

Hyponatremia.

Creatinine and Blood Urea Nitrogen

Increases in creatinine levels occurred in 1.1% of patients receiving MAVIK alone and 7.3% of patients treated with MAVIK, a calcium ion antagonist and a diuretic. Increases in blood urea nitrogen levels occurred in 0.6% of patients receiving MAVIK alone and 1.4% of patients receiving MAVIK, a calcium ion antagonist, and a diuretic. None of these increases required discontinuation of treatment. Increases in these laboratory values are more likely to occur in patients with renal insufficiency or those pretreated with a diuretic and, based on experience with other ACE inhibitors, would be expected to be especially likely in patients with renal artery stenosis. (see PRECAUTIONS and WARNINGS.)

Liver Function Tests

Occasional elevation of transaminases at the rate of 3X upper normals occurred in 0.8% of patients and persistent increase in bilirubin occurred in 0.2% of patients. Discontinuation for elevated liver enzymes occurred in 0.2% of patients.

Other

Another potentially important adverse experience, eosinophilic pneumonitis, has been attributed to other ACE inhibitors.



REPORTS OF SUSPECTED MAVIK SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Mavik. The information is not vetted and should not be considered as verified clinical evidence.

Possible Mavik side effects / adverse reactions in 54 year old female

Reported by a individual with unspecified qualification from Canada on 2012-01-13

Patient: 54 year old female

Reactions: Psychotic Disorder, Hallucination, Auditory, Paranoia

Adverse event resulted in: hospitalization

Suspect drug(s):
Imipramine HCL TAB
    Dosage: 25.0 mg/bid po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Plavix
    Dosage: 75.0 mg/daily po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

TAB Domperidone
    Dosage: 10 mg/bid po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Mavik
    Dosage: 2.0 mg/daily po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Pantoprazole
    Dosage: 40.0 mg/daily unk
    Indication: Product Used FOR Unknown Indication

Sucralfate
    Dosage: 1000.0 mg/bid unk

Desloratadine
    Dosage: 5.0 mg/daily unk

Zetia
    Dosage: 10 mg/daily po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Crestor
    Dosage: 20 mg/daily po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Macrobid
    Dosage: 100.0 mg/daily po
    Administration route: Oral

Atenolol
    Dosage: 50 mg/daily po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Detrol LA
    Dosage: 4.0 mg/daily po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Stelara
    Dosage: sc
    Indication: Product Used FOR Unknown Indication

Alvesco
    Dosage: 400 microgm/unk po
    Administration route: Oral

Aspirin
    Dosage: unk po
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Singulair



Possible Mavik side effects / adverse reactions in 25 year old female

Reported by a pharmacist from Canada on 2012-01-20

Patient: 25 year old female

Reactions: Convulsion

Adverse event resulted in: hospitalization

Suspect drug(s):
Escitalopram
    Dosage: daily dose + frequency not reported
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Mavik
    Dosage: daily dose + frequency not reported
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Amitriptyline HCL
    Dosage: daily dose + frequency not reported
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication

Other drugs received by patient: Laxatives



Possible Mavik side effects / adverse reactions in 54 year old female

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-01-23

Patient: 54 year old female weighing 77.6 kg (170.6 pounds)

Reactions: Psychotic Disorder, Hallucination, Auditory, Paranoia

Adverse event resulted in: hospitalization

Suspect drug(s):
Crestor
    Dosage: 20 mg;qd

Alvesco
    Dosage: 400 mcg

Aspirin
    Dosage: qd

Mavik
    Dosage: 2 mg;qd;sc
    Indication: Product Used FOR Unknown Indication

Pantoprazole
    Dosage: 40 mg;qd
    Indication: Product Used FOR Unknown Indication

Detrol LA
    Dosage: 4 mg;qd

Macrobid
    Dosage: 100 mg;qd
    Indication: Product Used FOR Unknown Indication

Plavix
    Dosage: 75 mg;qd
    Indication: Product Used FOR Unknown Indication

Ezetimibe
    Dosage: 10 mg;qd
    Indication: Product Used FOR Unknown Indication

Stelara
    Dosage: sc
    Indication: Product Used FOR Unknown Indication

Desloratadine
    Dosage: 5 mg;qd

Sucralfate
    Dosage: 1000 mg;bid
    Indication: Product Used FOR Unknown Indication

Domperidone (Domperidone)
    Dosage: 10 mg;bid

Imipramine
    Dosage: 25 mg;bid
    Indication: Product Used FOR Unknown Indication

Atenolol
    Dosage: 50 mg;qd

Other drugs received by patient: Singulair



See index of all Mavik side effect reports >>

Drug label data at the top of this Page last updated: 2012-02-14

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017